You just read:

Biohaven Receives FDA May Proceed Letter For Phase 3 Clinical Trial Of BHV-3241 For Multiple System Atrophy

News provided by

Biohaven Pharmaceutical Holding Company Ltd.

Jan 23, 2019, 03:00 ET